Luminex Wins Canadian Approval for xTAG Respiratory Viral Panel
Luminex, a provider of multiplexed solutions, has received clearance from Health Canada for its xTAG respiratory viral panel.
xTAG respiratory viral panel (RVP) is a unique test that, from one patient sample, simultaneously detects the 18 respiratory viruses and subtypes that are responsible for the majority of respiratory viral infections.
Based on Luminex’s xMAP multiplexing technology, xTAG RVP was created by Luminex Molecular Diagnostics in Toronto in partnership with a team of virologists and infectious disease specialists including James Mahony, professor of pathology and molecular medicine at McMaster University in Hamilton, Ontario, Canada.
xTAG RVP tests can be purchased through Abbott Molecular globally and through Abbott Molecular and Fisher HealthCare in the US.
Patrick Balthrop, president and CEO of Luminex, said: “xTAG RVP has the ability to improve patient care and enhance the surveillance of viruses in communities. This new clearance represents an important milestone for Luminex in the fulfillment of our mission to improve the health of people worldwide.”